A Weill Cornell Medicine team has found that triple-negative breast cancer depends on the enzyme EZH2 to spread. By silencing ...

Triple negative breast cancer (TNBC) is one of the most aggressive and hardest forms of breast cancer to treat, but a new ...

Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...

Researchers have discovered that an enzyme called EZH2 drives TNBC cells to divide abnormally, which enables them to relocate ...

Scientists at the Francis Crick Institute have developed a new cancer therapy that halts tumour growth without harming healthy cells, now entering human trials.

Before cells can divide, they first need to replicate all of their chromosomes, so that each of the daughter cells can ...

Good news for a grave concern. Researchers believe a groundbreaking new drug can offer hope to those diagnosed with this ...

For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before ...

Tumor cells collected during the removal of a cancerous bladder and - in some cases - transplanted into mice with weakened immune systems, could help physicians rapidly identify high-risk cancers, ...

“Our goal is really to get out all the cancer,” says Dr. Arvind Bakhru. In the operating room, the gynecologic oncologist relies on sight and feel to help identify the cancerous lesions he’ll remove.

The Food and Drug Administration (FDA) has approved Libtayo (cemiplimab-rwlc) for the adjuvant, or postsurgical, treatment of ...